<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-8123</journal-id>
<journal-title><![CDATA[Revista Colombiana de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Colomb.Reumatol.]]></abbrev-journal-title>
<issn>0121-8123</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Reumatología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-81232025000300216</article-id>
<article-id pub-id-type="doi">10.1016/j.rcreu.2024.03.007</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Prevalence of comorbidities and use of medication in psoriatic arthritis patients: findings from a Mexican cohort]]></article-title>
<article-title xml:lang="es"><![CDATA[Prevalencia de comorbilidades y uso de medicamentos en pacientes con artritis psoriásica: hallazgos de una cohorte mexicana]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vega-Morales]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garza-Alpirez]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Guerra]]></surname>
<given-names><![CDATA[María Fernanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montoya-Montes]]></surname>
<given-names><![CDATA[Alondra Elizabeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General de Zona Número 17 Rheumatology Service and Infusion Center Mexican Institute of Social Security (IMSS)]]></institution>
<addr-line><![CDATA[Monterrey Nuevo León]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Monterrey Institute of Technology and Higher Education  ]]></institution>
<addr-line><![CDATA[Monterrey Nuevo León]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2025</year>
</pub-date>
<volume>32</volume>
<numero>3</numero>
<fpage>216</fpage>
<lpage>221</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-81232025000300216&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-81232025000300216&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-81232025000300216&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Comorbidities contribute to the development of PsA and worsen disease severity. The aim of the study is to describe the clinical characteristics of Mexican PsA patients focusing on comorbidities and medications. The primary objective of our study was to investigate the clinical and epidemiological characteristics of patients with Psoriatic Arthritis (APs) who were undergoing treatment with biological disease-modifying antirheumatic drugs (bDMARDs).  Materials and methods:  We conducted a cross-sectional observational study in a secondary care clinic in northern Mexico.  Results:  Of the total sample, 38/66 (57.5%) were women, with a mean age of 47.8 (SD 11.5) years, a mean weight of 83.8 (SD 19) kg, and BMI of 31.5 (SD 6.5) kg/m2. Smoking and alcoholism were reported in 10/66 (15.1%) and 2 (3%) of patients, respectively. Obesity occurred in 41 (62.1%) patients, followed by diabetes mellitus in 23 (34.8%) patients, and systemic arterial hypertension in 19 (28.7%) patients. Ischaemic heart disease, heart failure, and cancer were not present in any of the patients.  Conclusions:  0ur study revealed a higher prevalence of chronic metabolic diseases among patients with psoriatic arthritis (PsA) compared to other cohorts without inflammatory arthropathy and the Mexican population.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Las comorbilidades contribuyen al desarrollo de la artritis psoriásica (APs) y empeoran la gravedad de la enfermedad. El objetivo del estudio es describir las características clínicas de pacientes mexicanos con APs, centrándose en las comorbilidades y los medicamentos. El objetivo principal de nuestro estudio fue investigar las características clínicas y epidemiológicas de los pacientes con APs que estaban en tratamiento con fármacos antirreumáticos modificadores de la enfermedad biológicos (bDMARDs).  Materiales y métodos : Realizamos un estudio observacional transversal en una clínica de atención secundaria en el norte de México.  Resultados:  De la muestra total, 38/66 (57,5%) eran mujeres, con una edad media de 47,8 (desviación estándar [DE] 11,5) años, peso medio de 83,8 (DE 19) kg y un índice de masa coporal (IMC) de 31,5 (DE 6,5) kg/m2. Se informó tabaquismo en 10/66 (15,1%) y alcoholismo en dos (3%) de los pacientes, respectivamente. La obesidad se presentó en 41 (62,1%) pacientes, seguida de diabetes mellitus en 23 (34,8%) pacientes e hipertensión arterial sistémica en 19 (28,7%) pacientes. La enfermedad cardiaca isquémica, la insuficiencia cardiaca y el cáncer no estuvieron presentes en ninguno de los pacientes.  Conclusiones:  Nuestro estudio reveló una mayor prevalencia de enfermedades metabólicas crónicas entre los pacientes con APs) en comparación con otras cohortes sin artropatía inflamatoria y con la población mexicana.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Psoriatic arthritis]]></kwd>
<kwd lng="en"><![CDATA[Comorbidities]]></kwd>
<kwd lng="en"><![CDATA[Diseases]]></kwd>
<kwd lng="en"><![CDATA[Treatment]]></kwd>
<kwd lng="es"><![CDATA[Artritis psoriásica]]></kwd>
<kwd lng="es"><![CDATA[Comorbilidades]]></kwd>
<kwd lng="es"><![CDATA[Enfermedades]]></kwd>
<kwd lng="es"><![CDATA[Tratamiento]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Jaleel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Magrey]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Racial disparities in comorbidities of patients with psoriatic arthritis]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2023</year>
<numero>43</numero>
<issue>43</issue>
<page-range>1525-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FitzGerald]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Ogdie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chandran]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Coates]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Kavanaugh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tillett]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psoriatic arthritis]]></article-title>
<source><![CDATA[Nat Rev Dis Primers]]></source>
<year>2021</year>
<numero>7</numero>
<issue>7</issue>
<page-range>59</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alajmi]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Alamoudi]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Alabbasi]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Alwagdani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alraddadi]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Alamri]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patterns of comorbidities in psoriasis patients: A cross-sectional study]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2021</year>
<numero>13</numero>
<issue>13</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gremese]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tolusso]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gigante]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Ferraccioli]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases).]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2014</year>
<numero>5</numero>
<issue>5</issue>
<page-range>576</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Syrimi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[SS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comorbidities in psoriatic arthritis: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2021</year>
<numero>41</numero>
<issue>41</issue>
<page-range>275-84</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumthekar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ogdie]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and psoriatic arthritis: A narrative review]]></article-title>
<source><![CDATA[Rheumatol Ther]]></source>
<year>2020</year>
<numero>7</numero>
<issue>7</issue>
<page-range>447-56</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogdie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Greenberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Curtis]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Harrold]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2019</year>
<numero>46</numero>
<issue>46</issue>
<page-range>475-82</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coates]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Helliwell]]></surname>
<given-names><![CDATA[PS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psoriatic arthritis: state of the art review]]></article-title>
<source><![CDATA[Clin Med (Lond).]]></source>
<year>2017</year>
<numero>17</numero>
<issue>17</issue>
<page-range>65-70</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galarza-Delgado]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Azpiri-Lopez]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Colunga-Pedraza]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cárdenas-de la Garza]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Vera-Pineda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wah-Suárez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of comorbidities in Mexican mestizo patients with rheumatoid arthritis]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2017</year>
<numero>37</numero>
<issue>37</issue>
<page-range>1507-11</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Albrecht]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Regierer]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Strangfeld]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marschall]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Callhoff]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex]]></article-title>
<source><![CDATA[RMD Open]]></source>
<year>2023</year>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Paris]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mellars]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Changolkar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mease]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world burden of comorbidities in US patients with psoriatic arthritis]]></article-title>
<source><![CDATA[RMD Open]]></source>
<year>2017</year>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamata]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tada]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: A literature review.]]></article-title>
<source><![CDATA[Int J Mol Sci.]]></source>
<year>2020</year>
<numero>21</numero>
<issue>21</issue>
<page-range>1690</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roubille]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Richer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Starnino]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[McCourt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[McFarlane]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fleming]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2015</year>
<numero>74</numero>
<issue>74</issue>
<page-range>480-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masnoon]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Shakib]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kalisch-Ellett]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Caughey]]></surname>
<given-names><![CDATA[GE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What is polypharmacy? A systematic review of definitions.]]></article-title>
<source><![CDATA[BMC Geriat]]></source>
<year>2017</year>
<numero>17</numero>
<issue>17</issue>
<page-range>230</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alp]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Palanbek Yavas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Taçdemir]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ketenci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kara]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Ozduran]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of polypharmacy on rheumatoid and psoriatic arthritis treatment: retrospective study]]></article-title>
<source><![CDATA[PeerJ]]></source>
<year>2023</year>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meraya]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Dwibedi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sambamoorthi]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polypharmacy and health-related quality of life among US adults with arthritis, medical expenditure panel survey, 2010-2012]]></article-title>
<source><![CDATA[Prev Chronic Dis]]></source>
<year>2016</year>
<numero>13</numero>
<issue>13</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inciarte-Mundo J]]></surname>
<given-names><![CDATA[Hernández MV]]></given-names>
</name>
<name>
<surname><![CDATA[Rosario V]]></surname>
<given-names><![CDATA[Ruíz-EsquideV]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera-Villalba S]]></surname>
<given-names><![CDATA[Ramírez J]]></given-names>
</name>
<name>
<surname><![CDATA[Caiiete JD]]></surname>
<given-names><![CDATA[Sanmartí R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reducción de dosis de terapias biológicas en enfermedades reumáticas: análisis descriptivo de 153 pacientes en condiciones de práctica clínica]]></article-title>
<source><![CDATA[Reumatol Clin]]></source>
<year>2014</year>
<numero>10</numero>
<issue>10</issue>
<page-range>10-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhole]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Vera Kellet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lacaille]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Gladman]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Dutz]]></surname>
<given-names><![CDATA[JP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differences in body mass index among individuals with PsA, psoriasis, RA and the general population]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2012</year>
<numero>51</numero>
<issue>51</issue>
<page-range>552-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shamah-Levy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Romero-Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barrientos-Gutiérrez]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Cuevas-Nasu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bautista-Arredondo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Colchero]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Encuesta Nacional de Salud y Nutrición 2021 sobre COVID-19. Resultados nacionales]]></article-title>
<source><![CDATA[National Survey of Health and Nutrition 2021 on COVID-19. National results]]></source>
<year>2022</year>
<publisher-name><![CDATA[Instituto Nacional de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
